Image by Getty / FuturismEli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a “shocking first miss” in its most recent quarterly sales announcement: in spite of bottomless hype, there just aren’t enough people getting on its new weight loss drugs.Shares plummeted by almost eight percent on Wednesday, with Zepbound and diabetes drug Mounjaro — the active ingredient in both is tirzepatide, a GLP-1 receptor agonist — missing Wall Street estimates by almost $900 million in sales.That’s despite the astronomical fanfare around weight loss drugs like…
